BiotechTube

Sonelokimab

Phase 3Recruiting
0 watching 0 views this week📈 Rising
72
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hidradenitis Suppurativa

Conditions

Hidradenitis Suppurativa

Trial Timeline

Dec 30, 2024 → Mar 27, 2026

NCT ID
NCT06768671

About Sonelokimab

Sonelokimab is a phase 3 stage product being developed by MoonLake Immunotherapeutics for Hidradenitis Suppurativa. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06768671. Target conditions include Hidradenitis Suppurativa.

Hype Score Breakdown

Clinical
27
Activity
18
Company
5
Novelty
9
Community
10

Clinical Trials (3)

NCT IDPhaseStatus
NCT07223138Phase 3Recruiting
NCT07007637Phase 3Recruiting
NCT06768671Phase 3Recruiting

Competing Products

20 competing products in Hidradenitis Suppurativa

See all competitors
ProductCompanyStageHype Score
SonelokimabMoonLake ImmunotherapeuticsPhase 3
72
Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
72
Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3
72
Sonelokimab (M1095) + AdalimumabMoonLake ImmunotherapeuticsPhase 2
47
Eltrekibart + PlaceboEli LillyPhase 2
52
Placebo + LY3041658Eli LillyPhase 2
52
Placebo + AdalimumabAbbVieApproved
85
Lutikizumab + PlaceboAbbViePhase 3
77
AdalimumabAbbViePre-clinical
23
Upadacitinib + PlaceboAbbViePhase 3
77
adalimumab + placeboAbbViePhase 3
77
LutikizumabAbbViePhase 2
52
adalimumabAbbViePhase 3
77
Lutikizumab + PlaceboAbbViePhase 2
52
Risankizumab + Placebo for risankizumabAbbViePhase 2
52
adalimumabAbbViePhase 3
77
adalimumab + placeboAbbViePhase 3
77
Upadacitinib + PlaceboAbbViePhase 2
52
MEDI8968 + SalineAstraZenecaPhase 2
52
AnifrolumabAstraZenecaPhase 2
52

Other Products from MoonLake Immunotherapeutics

SonelokimabPhase 3
72
Sonelokimab + Placebo + RisankizumabPhase 3
72
Sonelokimab + PlaceboPhase 3
72
SonelokimabPhase 3
72
Sonelokimab + PlaceboPhase 3
72